Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine.

Authors

Chaitanya Kurhade, Wei Chen, Weiqiang Li, Kristin R Tompkins, Lyndsey T Martinez, Swati Rajput, Emily Babiarz, Aaron Yam, Shin-Ae Lee, Shikha Shrivastava, Sarah O'Leary, Subrata Saha, Hui Yao, Li Hao, Todd Coffey, Carla Iris Cadima Couto, Alexander Muik, Raquel Munoz Moreno, Wesley Swanson, Pilar Mendoza, Uğur Şahin, Annaliesa S Anderson, Kena A Swanson, Pirada Suphaphiphat Allen, Kayvon Modjarrad

Published in

NPJ vaccines. Jul 06, 2026. Epub Jul 06, 2026.

Abstract

SARS-CoV-2 evolution toward antigenically distinct lineages drives escape from host immunity. JN.1 lineage derivatives have recently dominated the global epidemiologic landscape. In preclinical models, an LP.8.1-adapted BNT162b2 vaccine elicited higher serum neutralizing antibody responses against contemporary, circulating JN.1 sublineages, including the epidemiologically dominant XFG lineage, as compared to JN.1 and KP.2 vaccines. These findings supported the selection of an LP.8.1-adapted vaccine for the composition of the 2025-26 COVID-19 vaccine formula.

PMID:
42409841
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.